Repurposing the open access malaria box to discover potent inhibitors of Toxoplasma gondii and Entamoeba histolytica - Test2 - elhamkhani - TriplyDB

Repurposing the open access malaria box to discover potent inhibitors of Toxoplasma gondii and Entamoeba histolytica

Repurposing the open access malaria box to discover potent inhibitors of Toxoplasma gondii and Entamoeba histolytica

http://www.wikidata.org/entity/Q30487158

about

Open Source Drug Discovery with the Malaria Box Compound Collection for Neglected Diseases and Beyond Recent advances in Entamoeba biology: RNA interference, drug discovery, and gut microbiome Screening of the Open Source Malaria Box Reveals an Early Lead Compound for the Treatment of Alveolar Echinococcosis Bilayer Effects of Antimalarial Compounds Biological characterization of chemically diverse compounds targeting the Plasmodium falciparum coenzyme A synthesis pathway In Vitro Screening of the Open-Source Medicines for Malaria Venture Malaria Box Reveals Novel Compounds with Profound Activities against Theileria annulata Schizonts Extensive Shared Chemosensitivity between Malaria and Babesiosis Blood-Stage Parasites.New paradigms for understanding and step changes in treating active and chronic, persistent apicomplexan infections.Metabolomic Profiling of the Malaria Box Reveals Antimalarial Target Pathways.Review of Experimental Compounds Demonstrating Anti-Toxoplasma Activity.A Systematic Review of In vitro and In vivo Activities of Anti-Toxoplasma Drugs and Compounds (2006-2016).A novel in vitro image-based assay identifies new drug leads for giardiasis.Screening the Medicines for Malaria Venture Pathogen Box across Multiple Pathogens Reclassifies Starting Points for Open-Source Drug Discovery.In vitro activity of the interaction between taxifolin (dihydroquercetin) and pyrimethamine against Toxoplasma gondii.Extracts from Annona Muricata L. and Annona Reticulata L. (Annonaceae) Potently and Selectively Inhibit Plasmodium Falciparum.Characterization of Plasmodium Atg3-Atg8 interaction inhibitors identifies novel alternative mechanisms of action in Toxoplasma gondii.Discovery of New Inhibitors of Toxoplasma gondii via the Pathogen Box.Targeted Phenotypic Screening in Plasmodium falciparum and Toxoplasma gondii Reveals Novel Modes of Action of Medicines for Malaria Venture Malaria Box Molecules.Evaluation of Current and Emerging Antimalarial Medicines for Inhibition of Toxoplasma gondii Growth in Vitro

P2860

Q27826351-5E2B7AF2-1E7B-4442-BBCC-C9E228C6861D Q28077685-F5A84253-5510-44B9-AF53-E62896D3D3D8 Q28550703-92C24D7E-12C5-423D-B0A2-21B4A0CAD488 Q28550778-69CA7BEF-7DDF-4DAF-A8B5-3B7E308ECCE8 Q28821118-711BCE5B-5B09-41DE-99D9-7CFF4F38EA13 Q30489095-F534D105-1082-4387-9260-88E4AC8791CC Q30788575-67CEA70F-F3C1-40B2-ACE4-406055B60F32 Q37093155-C8422ECE-3D11-4AC1-A107-11141436EE02 Q37358648-1A74D008-CA35-43EE-B866-21535F5359D2 Q37428599-9D598AEC-7129-4F5D-B30F-56C985AE55DD Q37594988-2D7F25FD-0E67-4F77-A7F3-A4BE81F98027 Q37629375-B9B3C4F6-CE2E-48BB-8995-06833ACB8A23 Q38695331-8077AAED-C582-45CF-8EC9-CBF95D6E5D34 Q40139828-874F30DC-7122-4DB4-B5F3-936BFD8417FE Q41167557-45C0D9D1-E4C2-42E6-B52A-40A5AEA3B6BD Q47381598-7D12D9A5-6BA5-491F-B85C-0D3116268B57 Q48016385-E9A82667-4648-4ACC-A6B5-83A9891067F1 Q48022900-CF4BBBBD-113A-4C82-B3E1-AE4F24E315CF Q56344152-DAF7D8CC-52E8-41FB-95D6-FDD5D5171C14

P2860

Repurposing the open access malaria box to discover potent inhibitors of Toxoplasma gondii and Entamoeba histolytica

http://www.wikidata.org/entity/Q30487158

description

2014 nî lūn-bûn

@nan

2014 թուականի Յուլիսին հրատարակուած գիտական յօդուած

@hyw

2014 թվականի հուլիսին հրատարակված գիտական հոդված

@hy

2014年の論文

@ja

2014年論文

@yue

2014年論文

@zh-hant

2014年論文

@zh-hk

2014年論文

@zh-mo

2014年論文

@zh-tw

2014年论文

@wuu

name

Repurposing the open access ma ...... ndii and Entamoeba histolytica

@ast

Repurposing the open access ma ...... ndii and Entamoeba histolytica

@en

type

label

Repurposing the open access ma ...... ndii and Entamoeba histolytica

@ast

Repurposing the open access ma ...... ndii and Entamoeba histolytica

@en

prefLabel

Repurposing the open access ma ...... ndii and Entamoeba histolytica

@ast

Repurposing the open access ma ...... ndii and Entamoeba histolytica

@en

P1433

Q30487158-A49BB04C-9B59-44E0-ADD3-2F260C314235

P1476

Q30487158-41435B4D-CB6C-4AC2-B9CD-EDBC23311593

P2093

Q30487158-1E2081DA-65CB-4F79-9CD1-05940D3C9FC1

Q30487158-2BF1B3F8-EE8E-4DCC-B4F1-770D625EF19F

Q30487158-69651786-04BE-4BFD-9671-95F802FCCA18

Q30487158-6A88F374-DCBB-4A69-AABF-E1D1691FB3E9

Q30487158-83B31CB3-4C9A-43D6-BC79-3195A6902E17

Q30487158-B014DF1C-EAB6-4AA2-A6AD-6F169C4161E3

Q30487158-CC264761-4EFD-4724-B231-E217DEB56B5D

Q30487158-D626AA92-3B53-4321-9E7C-D4D1A127BF18

Q30487158-DB276C6C-6C48-4260-B544-F1FC737CCBB3

P2860

Q30487158-0ABEC353-A7DB-4294-9214-1981095F03CC

Q30487158-12360CE6-08B2-41EF-A11C-128CBE047687

Q30487158-161FAD58-115A-4EA2-9E21-15108F73331E

Q30487158-1ED164E3-651F-4CAF-B31E-FA6D20F20D41

Q30487158-2E36ABDB-2A0F-428A-852D-7E8290E90E48

Q30487158-3A164F0D-C624-4543-A8A2-C1066277D5D9

Q30487158-3C3A734A-BE7C-4710-B438-08F7E63155BB

Q30487158-4DB0E1AB-BCCE-40E5-9297-78724C78C7BB

Q30487158-54BCF792-827D-48DC-AF1B-A03A763B7992

Q30487158-572C25C9-F09B-4973-9019-C48EC8C5DC8C

P304

Q30487158-1D3A8727-C2E0-438A-92AC-B46A5F33BCAB

P31

Q30487158-3D100329-6D2B-4ACC-86F7-19BEEB95C506

P356

Q30487158-1173E641-E92D-481B-A28E-93724BEA8622

P407

Q30487158-725F3322-DE8B-4694-83A3-1A8797FBF520

P433

Q30487158-E1851014-EA5F-4E7C-833E-B8E0380A6865

P478

Q30487158-16427E63-8079-435E-8084-74EB60D48115

P577

Q30487158-5096A2AB-DB1A-43BF-ABD6-9444F190C5CA

P5875

Q30487158-70A63850-3E6B-462E-992E-A144188F4EBC

P698

Q30487158-3E5E51B4-D6F0-4B42-98B4-FA614A09CAAC

P921

Q30487158-101FACC4-73ED-47E5-9490-99CE7C0D2DA6

Q30487158-6771CE6A-1E26-4D2C-8488-959CC668250D

Q30487158-B4601B07-79CB-47AB-B0F7-D96DB8139D7E

P932

Q30487158-F8C8A3C3-AEAA-4652-94BD-55E640E0BA28

P356

P1433

Antimicrobial Agents and Chemotherapy

P1476

Repurposing the open access ma ...... ndii and Entamoeba histolytica

@en

P2093

Alvine N Mfopa

http://www.w3.org/2001/XMLSchema#string

Cedric J Mbouna

http://www.w3.org/2001/XMLSchema#string

Fabrice F Boyom

http://www.w3.org/2001/XMLSchema#string

Lauve R Y Tchokouaha

http://www.w3.org/2001/XMLSchema#string

Patrick V T Fokou

http://www.w3.org/2001/XMLSchema#string

Paul H A Zollo

http://www.w3.org/2001/XMLSchema#string

Ruffin M T Kouipou

http://www.w3.org/2001/XMLSchema#string

Thomas Spangenberg

http://www.w3.org/2001/XMLSchema#string

Valerie F Donkeng Donfack

http://www.w3.org/2001/XMLSchema#string

P2860

Foodborne illness acquired in the United States--major pathogens

A high-throughput drug screen for Entamoeba histolytica identifies a new lead and target

Endochin-like quinolones are highly efficacious against acute and latent experimental toxoplasmosis

Laboratory diagnostic techniques for Entamoeba species

Identification and Development of Novel Inhibitors of Toxoplasma gondii Enoyl Reductase

Efficacy of atovaquone combined with clindamycin against murine infection with a cystogenic (Me49) strain of Toxoplasma gondii

Anti-toxoplasma activities of antiretroviral drugs and interactions with pyrimethamine and sulfadiazine in vitro

The open access malaria box: a drug discovery catalyst for neglected diseases

Opportunities and Challenges in Antiparasitic Drug Discovery

Recent highlights in anti-protozoan drug development and resistance research.

P304

5848-5854

http://www.w3.org/2001/XMLSchema#string

P31

scholarly article

P356

10.1128/AAC.02541-14

http://www.w3.org/2001/XMLSchema#string

P407

P433

10

http://www.w3.org/2001/XMLSchema#string

P478

58

http://www.w3.org/2001/XMLSchema#string

P577

2014-07-21T00:00:00Z

http://www.w3.org/2001/XMLSchema#dateTime

P5875

264128495

http://www.w3.org/2001/XMLSchema#string

P698

25049259

http://www.w3.org/2001/XMLSchema#string

P921

Toxoplasma gondii

Entamoeba histolytica

P932

4187973

http://www.w3.org/2001/XMLSchema#string